EuroBiotech Report—Autolus delay, Novartis sale, Sonnet deal, Y-mAbs and the U.K.

Map of Europe
(Pixabay)

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week at Autolus, which revealed a manufacturing delay is holding up multiple CAR-T clinical development programs. Elsewhere, Novartis licensed late-phase rare genetic disease treatment leniolisib to Pharming. Sonnet BioTherapeutics picked up an experimental treatment for chemotherapy-induced peripheral neuropathy that was once in Merck KGaA's pipeline. Y-mAbs Therapeutics revealed the extent of its hiring since last year's IPO. The U.K. made a pitch to attract the best of the world's scientists. And more. — Nick Taylor
 
1. Autolus delays multiple CAR-T clinical programs
 
A manufacturing delay is stymying progress of a clutch of Autolus’ CAR-T programs. Autolus revealed the setbacks alongside news that it is dumping the first-generation version of AUTO2 in the face of tough competition in the BCMA space.

2. Novartis sells phase 3 rare disease drug to Pharming

Pharming has licensed late-phase rare genetic disease treatment leniolisib from Novartis for $20 million (€17.9 million) upfront. The immunomodulator could come to market in activated PI3K-delta syndrome (APDS) in the second half of 2021. 
 
3. Sonnet bags ex-Serono neuropathy drug via Relief Therapeutics deal
 
Sonnet BioTherapeutics has struck a deal to acquire an ex-Serono drug from Relief Therapeutics. The agreement tees Sonnet up to advance the asset in chemotherapy-induced peripheral neuropathy (CIPN) using an equity facility worth up to $100 million (€89 million).

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

4. Y-mAbs ramps up headcount in post-IPO hiring spree

Y-mAbs Therapeutics has rapidly expanded its headcount by 65%. The post-IPO hiring spree comes as Y-mAbs heads toward FDA filings of two cancer drugs later this year.
 
5. U.K. plans post-Brexit easing of rules on migrant scientists
 
The U.K. is set to open its doors to top scientists in a bid to retain and strengthen its leading position in the field after Brexit. Through a series of reforms, U.K. Prime Minister Boris Johnson aims to create a fast-track immigration route that facilitates the flow of talent from around the world. 

And more articles of note>>    

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.